Antibiotic S 31794/F-1

Claim 2

A compound S 31794/F-1 having the following characteristics: λ MAX 194 nm E 1 cm 1% =807, λ MAX 225 nm (shoulder) E 1 cm 1% =132, λ MAX 276 nm E 1 cm 1% =12.8, λ MAX 284 nm (shoulder) E 1 cm 1% =10.5, (see FIG. 1); 1 H NMR spectrum in deuterated DMSO (100 megacycles per second second) with tetramethylsilane as internal standard (see FIG. 4); 13 C NMR spectrum in deuterated methanol (D 4 ) with tetramethylsilane as internal standard (see Table 1); and having the following additional characteristics in amorphous form; elementary analysis: C 53.9%, H 7.5%, N 10.1%, O 27.3%; IR spectrum in kBr (see FIG. 2); and having the following additional characteristics in crystalline form: elementary analysis: C 55.5-56.5%, H 7.5-7.7%, N 10.5-10.8%, O 26.5-27.0%; IR spectrum in Nujol (see FIG. 3).

Claim 3

The compound of claim 1 in amorphous form.

Claim 4

The compound of claim 1 in crystalline form.

Claim 5

A process for the production of an antibiotic S 31794/F-1 having the following characteristics: UV spectrum in methanol: λ MAX 194 nm E 1 cm 1% =807, λ MAX 225 nm (shoulder) E 1 cm 1% =132, λ MAX 276 nm E 1 cm 1% =12.8, λ MAX 284 nm (shoulder) E 1 cm 1% =10.5, (see FIG. 1); 1 H NMR spectrum in deuterated DMSO (100 megacycles per second second) with tetramethylsilane as internal standard (see FIG. 4); 13 C NMR spectrum in deuterated methanol (D 4 ) with tetramethylsilane as internal standard (see Table 1); and having the following additional characteristics in amorphous form: elementary analysis: C 53.9%, H 7.5%, N 10.1%, O 27.3%; IR spectrum in kBr (see FIG. 2); and having the following additional characteristics in crystalline form; elementary analysis: C 55.5-56.5%, H 7.5-7.7%, N 10.5-10.8%, O 26.5-27.0%; IR spectrum in Nujol (see FIG. 3); which comprises cultivating the strain NRRL 8095 of Acrophialophora limonispora nov. spec. Dreyfus+Muller under aerobic fermentation conditions in a nutrient medium until a sufficient amount of antibiotic S 31794/F-1 is produced.

Claim 6

A process for the production of an antibiotic S 31794/F-1 having the following characteristics: UV spectrum in methanol: λ MAX 194 nm E 1 cm 1% =807, λ MAX 225 nm (shoulder) E 1 cm 1% =132, λ MAX 276 nm E 1 cm 1% =12.8, λ MAX 284 nm (shoulder) E 1 cm 1% =10.5, (see FIG. 1); 1 H NMR spectrum in deuterated DMSO (100 megacycles per second second) with tetramethylsilane as internal standard (see FIG. 4); 13 C NMR spectrum in deuterated methanol (D 4 ) with tetramethylsilane as internal standard (see Table 1); and having the following additional characteristics in amorphous form: elementary analysis: C 53.9%, H 7.5%, N 10.1%, O 27.3%; IR spectrum in kBr (see FIG. 2); and having the following additional characteristics in crystalline form; elementary analysis: C 55.5-56.5%, H 7.5-7.7%, N 10.5-10.8%, O 26.5-27.0%; IR spectrum in Nujol (see FIG. 3); which comprises cultivating the strain NRRL 8095 of Acrophialophora limonispora nov. spec. Dreyfus+Muller under aerobic fermentation conditions in a nutrient medium until a sufficient amount of antibiotic S 31794/F-1 is produced.

Claim 7

A pharmaceutical composition for treating Candida albicans comprising a Canadida albicans inhibiting effective amount of a compound of claim 1 in association with a pharmaceutical carrier or diluent.

Claim 8

A method of combatting Candida albicans infections in animals which comprises administering a Candida albicans inhibiting effective amount of a compound of claim 1 to an animal in need of such treatment.